表皮生长因子受体III型变异体（EGFRvIII）肽纳米胶囊和贝伐单抗纳米胶囊：一种针对胶质母细胞瘤的鼻脑多靶点治疗方法
EGFRvIII peptide nanocapsules and bevacizumab nanocapsules: a nose-to-brain multitarget approach against glioblastoma.
作者信息
de Cristo Soares Alves Aline, Lavayen Vladimir, de Fraga Dias Amanda, Bruinsmann Franciele Aline, Scholl Juliete Nathali, Cé Rodrigo, Visioli Fernanda, Oliveira Battastini Ana Maria, Stanisçuaski Guterres Silvia, Figueiró Fabrício, Raffin Pohlmann Adriana
机构信息
Programa de Pós-Graduação em Ciências Farmacêuticas, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul, Av. Ipiranga, 2752, Porto Alegre, RS 90610-000, Brazil.
Departamento de Química Inorgânica, Instituto de Química, Universidade Federal do Rio Grande do Sul, Av. Bento Gonçalves, 9500, Porto Alegre, RS 91501-970, Brazil.
出版信息
Nanomedicine (Lond). 2021 Aug;16(20):1775-1790. doi: 10.2217/nnm-2021-0169. Epub 2021 Jul 27.
To evaluate the antitumor efficacy of bevacizumab-functionalized nanocapsules in a rat glioblastoma model after the pretreatment with nanocapsules functionalized with a peptide-specific to the epidermal growth factor receptor variant III. Nanocapsules were prepared, physicochemical characterized and intranasally administered to rats. Parameters such as tumor size, histopathological characteristics and infiltration of CD8 T lymphocytes were evaluated. The strategy of treatment resulted in a reduction of 87% in the tumor size compared with the control group and a higher infiltration of CD8 T lymphocytes in tumoral tissue. The block of two different molecular targets using nose-to-brain delivery represents a new and promising approach against glioblastoma.
在用表皮生长因子受体变体III特异性肽功能化的纳米胶囊预处理后，评估贝伐单抗功能化纳米胶囊在大鼠胶质母细胞瘤模型中的抗肿瘤疗效。制备纳米胶囊，对其进行理化表征并经鼻给予大鼠。评估肿瘤大小、组织病理学特征和CD8 T淋巴细胞浸润等参数。与对照组相比，该治疗策略使肿瘤大小减少了87%，肿瘤组织中CD8 T淋巴细胞浸润增加。利用鼻脑递送阻断两个不同分子靶点是一种针对胶质母细胞瘤的新的且有前景的方法。
Zotero 插件